The FDA has accepted for review the supplemental marketing application seeking approval for Dupixent (dupilumab). It is an add-on treatment for children aged 6 to 11 years with uncontrolled ...
Please provide your email address to receive an email when new articles are posted on . The 20-year cost of asthma will exceed $963 billion. Eosinophil counts may indicate who will best respond to ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a $3.02 billion market cap pharmaceutical company that has seen its stock rise 21% year-to-date, announced Friday it has submitted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results